Avicanna Expands its Epilepsy Research Program with a New Collaboration with the University of Toronto
15 September 2022 - 3:08PM
Avicanna Inc. (“
Avicanna” or the
“
Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN),
a commercial stage, international biopharmaceutical company focused
on the commercialization of evidence-based, cannabinoid-based
products, is pleased to announce that it has expanded its research
collaboration in field of Epilepsy with a new collaboration with
the University of Toronto and Dr. Mac Burnham’s research team to
explore the efficacy of Avicanna’s proprietary formulations in
pre-clinical models for Epilepsy.
New research collaboration with
University of Toronto
The research collaboration led by Dr. Mac
Burnham’s team will explore the efficacy of Avicanna’s drug
candidates including AVCN319302 in animal models for Epilepsy. In
addition, the research collaboration will evaluate the anti-seizure
properties of rare cannabinoids in isolation and in combination.
Dr. Burnham is a professor emeritus of pharmacology and toxicology
at the University of Toronto's Temerty Faculty of Medicine, and is
a co-director of EpLink, the Ontario Brain Institute’s Epilepsy
Research Program. He has over 150 publications and has contributed
greatly to the advancement of anti-seizure therapies.
According to Dr. Burnham, “The cannabinoids,
alone and in combination, are some of the most promising
antiseizure drugs that I have seen in many years of research.”
Ongoing research collaboration with
University Health Network
The research by Dr. Burnham’s team will expand
on an existing collaboration with the University Health
Network and Dr. Peter Carlen, a professor of medicine and
physiology at Temerty Faculty of Medicine, and senior scientist at
the Toronto Western Research Institute.
The previously reported, electrophysiological
studies on seizure induced wildtype cortical slices determined that
Avicanna’s proprietary drug candidate, AVCN319302, had significant
anti-convulsant effects and demonstrated strong potential to treat
patients diagnosed with intractable forms of Epilepsies and those
at risk of seizure-induced Sudden Unexpected Death.
“We are excited to continue expanding our
research on cannabinoids and their anti-seizure properties in the
field of Epilepsy and to be doing so with leading Canadian
institutions and key opinion leaders. In parallel, we are also
excited by the rate of early acceptance of our medical cannabis
formulation (RHO Phyto Micro Drop 50 CBD) by epilepsy patients,
where such early acceptance also provides real world data and
evidence. The combination of real-world evidence and ongoing
research collaborations enable us to further develop our
pharmaceutical pipeline and further progress our drug candidate in
the field of epilepsy,” noted Dr. Karolina Urban, Vice President
Scientific and Medical Affairs.
About Avicanna Inc.
Avicanna is a commercial-stage international
biopharmaceutical company focused on the advancement and
commercialization of evidence-based cannabinoid-based products for
the global medical and pharmaceutical market segments. Avicanna has
an established scientific platform including R&D and clinical
development that has led to the commercialization of more than
thirty products across various market segments:
Medical Cannabis & Wellness
Products: Marketed under the RHO Phyto™ brand these
medical and wellness products are a line of pharmaceutical-grade
cannabinoid products containing varying ratios of cannabidiol
(“CBD”) and tetrahydrocannabinol (“THC”). The product portfolio
contains a full formulary of products including oral, sublingual,
topical, and transdermal deliveries that have controlled dosing,
enhanced absorption and stability studies supported by pre-clinical
data. The formulary is marketed with consumer, patient and
medical-community education and training.
Pharmaceutical
Pipeline: Leveraging Avicanna’s scientific platform,
vertical integration, and real-world evidence, Avicanna has created
a pipeline of patent-pending drug candidates that are
indication-specific and in various stages of clinical development
and commercialization. These cannabinoid-based drug candidates look
to address unmet medical needs in the areas of dermatology, chronic
pain, and various neurological disorders. Avicanna’s first
pharmaceutical preparation (Trunerox™) is in the drug registration
stage in South America.
Click to watch Avicanna’s Corporate Video
2022
SOURCE Avicanna Inc.
Stay Connected
For more information about Avicanna, visit
www.avicanna.com, contact Ivana Maric by email at info@avicanna.com
or follow us on social media
on LinkedIn, Twitter, Facebook or Instagram.
The Company posts updates through videos from
the official Company YouTube channel.
Cautionary Note Regarding
Forward-Looking Information and Statements
This news release contains “forward-looking
information” within the meaning of applicable securities laws.
Forward-looking information contained in this news release may be
identified by the use of words such as, “may”, “would”, “could”,
“will”, “likely”, “expect”, “anticipate”, “believe, “intend”,
“plan”, “forecast”, “project”, “estimate”, “outlook” and other
similar expressions. Forward-looking information contained in this
news release includes, without limitation, statements related.
Although the Company believes that the expectations and assumptions
on which such forward looking information is based are reasonable,
undue reliance should not be placed on the forward-looking
information because the Company can give no assurance that they
will prove to be correct. Actual results and developments may
differ materially from those contemplated by these statements.
Forward-looking information is subject to a variety of risks and
uncertainties that could cause actual events or results to differ
materially from those projected in the forward-looking information.
Such risks and uncertainties include, but are not limited to,
current and future market conditions, including the market price of
the common shares of the Company, and the risk factors set out in
the Company’s annual information form dated March 31, 2022, filed
with the Canadian securities regulators and available under the
Company’s profile on SEDAR at www.sedar.com. The statements in this
news release are made as of the date of this release. The Company
disclaims any intent or obligation to update any forward-looking
information, whether as a result of new information, future events
or results or otherwise, other than as required by applicable
securities laws.
Avicanna (TSX:AVCN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Avicanna (TSX:AVCN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024